Costs of mini mental state examination-related cognitive impairment

PharmacoEconomics

Volumn 16, Issue 4, 1999, Pages 409-416

  Jönsson, Linus ^a   Lindgren, Peter ^a   Wimo, Anders ^a   Jönsson, Bengt ^a   Winblad, Bengt ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE SEVERITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MENTAL HEALTH; PRIORITY JOURNAL; SWEDEN;

AGED; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MENTAL STATUS SCHEDULE; MULTIVARIATE ANALYSIS; SWEDEN;

EID: 0032701613     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916040-00008     Document Type: Article

References (33)

1. Reisberg B, Ferns SH, Kluger A, et al. Symptomatic changes in CNS aging und dementia of the Alzheimer type: cross-sectional, temporal and remediable concomitants, in: Bergener M, Reisberg B, editors. Diagnosis and treatment of senile dementia. Berlin-Heidelberg: Springer Verlag, 1989: 193-223
2. Baines S, Saxby P, Ehlert K. Reality orientation and reminiscence therapy: a controlled cross-over study of confused people. Br J Psychiatry 1987; 151: 222-31
3. Wimo A, Eriksson T, Mattsson B, et al. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 1995; 11: 49-65
4. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991; 337: 989-92
5. Rogers SL, Freidhoff LT, the Donezepil Studs Group. The efficacy and safely of donezepil in patients with Alzheimer's Disease: results of a US multicentre, randomized, double-Wind, placebo-controlled trial. Dementia 1996; 7: 293-303
6. McRae A, Rudolphi K, Schubert P. Propenlofylline depresses amyloid and Alzheimer's CSF microglial antigens after ischaemia. Neuroreport 1994; 5: 1193-6
7. Winblad B, Hill S, Beermann B, et al. Issues in the economic evaluation of treatment for dementia. Alzheimer Dis Assoc Disord 1997: H Suppl. 3: 39-45
8. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 1991; 20: 736-48
9. Schneider EL, Guralnik JM. The aging of America: impact on health care costs. JAMA 1990; 263: 2335-40
10. Fratiglioni L, Grut M, Forsell Y, et al. Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex and education. Neurology 1991; 41: 1886-92
11. Corder F., Basun H, Lannfelt L. et al, Apolipoprotein Eε4 gene dose. Lancet 1995; 346: 907-8
12. 1966 Lancet Conference Writing Committee. The challenge of dementias. Lancet 1996; 347: 1303-7
13. Wimo A, Ljunggren G, Winblad B, Costs of dementia and dementia care: a review, Int J Geriatr Psychiatry 1997; 12: 841-56
14. Drummond MF, Mohide HA, Tew M, et al. Economic evaluation of a support program for caregivers of demented elderly. Int J Technol Assess Health Care 1992; 7: 209-19
15. Lubeck DP, Mazonson PD, Bowe T. The potential impact of tacrine on expenditures for Alzheimer's disease. Med Interface 1994; 7: 130-8
16. Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer's disease with tacrine; a cost analysis model. Alzheimer Dis Assoc Disord 1997; 11: 191-200
17. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). The efficacy of tacrine and the measurement of outcomes in Alzheimers disease. Ottawa (ON): CCOHTA, 1997
18. Sonnenberg FA, Beck JR, Markov models in decision making: a practical guide. Med Decis Making 1993; 13: 322-38
19. Folstein MF, Holstein SR. McHugh PR. "Mini-mental" stale: a practical method for grading the cognitive state of patients for the clinician. Psychiatry Res 1975; 12: 189-98
20. Koopmanschap MA, Polder JJ, Meering WJ, et al. Cost of dementia in the Netherlands. In: Wimo A, Jönsson B, Karlsson G, et at., editors. Health economics of dementia. Chichester:Wiley, 1998: 207-14
21. Fratighoni L, Forsell Y, Aguero Torres H, et al. Severity of dementia and institutionalization in the elderly: prevalence data from an urban area in Sweden. Neuroepidemiology 1994; 13: 79-88
22. Fratiglioni L, Viitanen M, von Strauss H, et al. Very old women at highest risk of dementia and Alzheimer's disease: incidence duty from the Kungsholmen project, Stockholm. Neurology 1997; 136: 132-8
23. Statistics Sweden, Consumer price index 1914-1995: statistiska meddelanden P 15 SM 9601, 1996. Stockholm; Statistics Sweden. 1996
24. The Federation of County Councils in Sweden. Kostnad per intagen patient, värddag, läkarbesök mm 1993. Stockholm: the Federation of County Councils in Sweden, 1994
25. Svensson M, Ctielwlk PG, Persson U. Group living for elderly patients with dementia: a cost analysts. Health Policy 1996; 38 (2): 83-100
26. The Federation of the Swedish Municipalities. Stockholm: The Federation of the Swedish Municipalities. (Data on file)
27. Pharmaceutical Specialities in Sweden (FASS). LINFO. Stockholm: Läkemedelsinformation AB, 1996
28. Wimo A, Mattsson B, Krakau I. et al. The impact of different levels of cognitive decline and work loud on costs of dementia care at different caring levels. Int J Geriatr Psychiatry 1994; 9: 479-89
29. Wimo A, Mattsson B, Gustafsson I,. Predictive validity of lactors influencing the institutionalization of elderly people with psycho-geriatric disorders, Scand J Prim Health Care 1992; 10: 185-91
30. Ernst RI., Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimers disease. Arch Neurol 1997; 54: 687-93
31. Boada M, Hart W, Pena J, et al. Estimated health and social cost of Alzheimer's disease in community patients in Spain. Alzheimer Disease International (ADI), Alzheimer Europe (AE) und Alüzheimer Society of Finland. Alzheimer: the blind hunter: 1997 Sep 29 Oct 1; Helsinki
32. Schulenburg JM, Schulenburg I, Horn R, et al. Cost of treatment and care of Alzheimer's disease in Germany. In: Wimo A, Jönsson B, Karlsson G, et al., editors. Health economics of dementia. Chichester: Wiley, 1998: 217-30
33. Fitsthom J, Giron MST. Drug costs in dementia care. In: Wimo A, Jönsson B, Karlsson G, et al., editors. Health economics of dementia. Chichester: Wiley, 1998: 285-14